Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

Hofman, Michael S; Hicks, Rodney J.

doi:10.1007/s00259-013-2621-6

Cited by 25 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neoplastic bone marrow involvement may increase the likelihood of myelotoxicity (Hubble et al 2010). The majority of renal events are mild if the necessary precautions (such as nephroprotective amino acid coadministration and therapy adaptation to the clinical scenario) are undertaken (Bodei et al 2009, Hofman & Hicks 2014. In a cumulative analysis of nine individual series, ~2500 patients/15 years, chronic and permanent effects to target organs were infrequent with 177 Lu-octreotate (Bodei et al 2016).…”

Section: Main Textmentioning

confidence: 99%

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

Bodei

Modlin

Luster

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) with 90 Y-octreotide or 177 Lu-octreotate is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic or bronchopulmonary NETs. PRRT is generally extremely well tolerated, with modest toxicity to target organs, kidney and bone marrow. Nevertheless, a priori concerns regarding long-term effects lead clinicians such as Brieau and coworkers, in this ERC issue, to ascribe to the combination of alkylating agents and PRRT the apparently high occurrence (n = 4) of myeloproliferative events (therapy-related myeloid neoplasms (t-MNs)) in a small cohort of 20 progressive, advanced digestive NETs treated with PRRT after chemotherapy. Anecdotal reports of myelotoxic events should be placed in the correct perspective of larger series, where the reported incidence of these events is ~2%, with the aim of promoting a balanced awareness of the issue and unbiased and reasonable overall conclusions. For a comprehensive definition of the issue, we provide an evaluation of the occurrence of t-MN in patients treated with various myelotoxic treatments. L Bodei et al. t-MN: myth and reality 23:8 Commentary

show abstract

Section: Main Textmentioning

confidence: 99%

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

Bodei

Modlin

Luster

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…While a standardized approach is likely to better meet the regulatory requirements for reimbursement, the need for a more individualized approach has also been argued [46]. This includes the potential use of PRRT in combination with other therapies in a manner analogous to chemoradiation, which is now widely used in the treatment of various solid tumours.…”

Section: Netter-1: the First Randomized Controlled Trial Of Prrtmentioning

confidence: 99%

“…The NETTER-1 trial used up to 4 cycles of a fixed administered activity of 7.4 GBq (200 mCi) per cycle, which is based on the protocol developed at the Erasmus Medical Center [82]. Variation from this administered activity based on tumour burden, extent of bone marrow involvement, renal function, and body habitus may be appropriate but must depend on local expertise and clinical judgment [46]. The potential role of prospective radiation dosimetry requires further clarification.…”

Section: Prrt Requirementsmentioning

confidence: 99%

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

et al. 2017

Self Cite

View full text Add to dashboard Cite

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish ¹⁷⁷Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.

show abstract

“…There is further room to optimize delivery of PRCRT by refinement in patient selection and delivery of therapy (9), including the use of 90 Y in patients with larger-volume disease and the use of newer chemotherapeutic combinations such as capecitabine and temozolomide for pancreatic NET (10). We are hopeful that these refinements will further improve patient outcomes.…”

mentioning

confidence: 99%

Modifying the Poor Prognosis Associated with ¹⁸F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

et al. 2015

Self Cite

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

Cited by 25 publications

References 17 publications

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Modifying the Poor Prognosis Associated with ¹⁸F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

Contact Info

Product

Resources

About

Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

Cited by 25 publications

References 17 publications

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Modifying the Poor Prognosis Associated with 18F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

Contact Info

Product

Resources

About

Modifying the Poor Prognosis Associated with ¹⁸F-FDG–Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)